Exploring AI Innovation: insitro CEO Daphne Koller On AI In Drug Discovery

Dean Lloyd Minor welcomes Daphne Koller, PhD, founder and CEO of insitro, for a conversation about AI’s potential to transform drug discovery. They discuss how machine learning algorithms can accelerate the drug design process, quickly identifying biological patterns and predicting outcomes. They also explore the challenges and opportunities of founding a startup in Silicon Valley, and how insitro’s collaborations with large pharmaceutical companies are advancing therapeutics for Amyotrophic lateral sclerosis (ALS) and other conditions.